Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD ASTRA
2021-006674-22Phase 2Active
- Sponsor
- Východoslovenský onkologický ústav
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Východoslovenský onkologický ústav. Primary endpoints: 5-year biochemical control rate and Clinically significant gastrointestinal and genitourinary toxicity. Started Oct 2022; status: active.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-006674-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006674-22.